JP2025518227A - mazdutideを使用する治療方法 - Google Patents

mazdutideを使用する治療方法 Download PDF

Info

Publication number
JP2025518227A
JP2025518227A JP2024570699A JP2024570699A JP2025518227A JP 2025518227 A JP2025518227 A JP 2025518227A JP 2024570699 A JP2024570699 A JP 2024570699A JP 2024570699 A JP2024570699 A JP 2024570699A JP 2025518227 A JP2025518227 A JP 2025518227A
Authority
JP
Japan
Prior art keywords
weeks
target compound
patient
week
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024570699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025518227A5 (cg-RX-API-DMAC7.html
Inventor
チョンハン ツァイ
モン リョウ
ホアン トン
パイリー ソン
チエ ウェン
Original Assignee
イノベント バイオロジクス(スーチョウ)カンパニー,リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス(スーチョウ)カンパニー,リミティド filed Critical イノベント バイオロジクス(スーチョウ)カンパニー,リミティド
Publication of JP2025518227A publication Critical patent/JP2025518227A/ja
Publication of JP2025518227A5 publication Critical patent/JP2025518227A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
JP2024570699A 2022-06-01 2023-05-10 mazdutideを使用する治療方法 Pending JP2025518227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210622648.7 2022-06-01
CN202210622648 2022-06-01
PCT/CN2023/093311 WO2023231730A2 (zh) 2022-06-01 2023-05-10 使用mazdutide的治疗方法

Publications (2)

Publication Number Publication Date
JP2025518227A true JP2025518227A (ja) 2025-06-12
JP2025518227A5 JP2025518227A5 (cg-RX-API-DMAC7.html) 2026-05-15

Family

ID=89026916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024570699A Pending JP2025518227A (ja) 2022-06-01 2023-05-10 mazdutideを使用する治療方法

Country Status (8)

Country Link
US (1) US20250296973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4534095A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025518227A (cg-RX-API-DMAC7.html)
KR (1) KR20250021331A (cg-RX-API-DMAC7.html)
CN (1) CN119584980A (cg-RX-API-DMAC7.html)
AU (1) AU2023281591A1 (cg-RX-API-DMAC7.html)
CA (1) CA3257926A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023231730A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用
EP4788362A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
WO2026002224A1 (en) * 2024-06-27 2026-01-02 Innovent Biologics (Suzhou) Co., Ltd. Method of treating polycystic ovary syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用

Also Published As

Publication number Publication date
US20250296973A1 (en) 2025-09-25
AU2023281591A1 (en) 2025-01-02
KR20250021331A (ko) 2025-02-12
CA3257926A1 (en) 2025-04-09
EP4534095A2 (en) 2025-04-09
EP4534095A4 (en) 2026-05-27
CN119584980A (zh) 2025-03-07
WO2023231730A3 (zh) 2024-01-25
WO2023231730A2 (zh) 2023-12-07

Similar Documents

Publication Publication Date Title
TW202323296A (zh) 組合療法
US20250296973A1 (en) Treatment method using mazdutide
RU2546520C2 (ru) Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
JP2024524273A (ja) マズチドの使用
JP2021515026A (ja) 肥満の治療および体重管理のためのglp−1組成物
JP2023510609A (ja) Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法
WO2024042518A1 (en) Glp-1 receptor antagonist and methods of use thereof
IL323508A (en) Methods and uses for treating nausea and vomiting
WO2024243243A1 (en) Treatment of adults with overweight or obesity with or without weight-related comorbidities
HK40118093A (en) Treatment method using mazdutide
CN115212293A (zh) 一种融合蛋白的制药用途
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
JP2023518645A (ja) Glp-1の投薬レジメン
TW202140061A (zh) 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
HK40110048A (en) Use of mazdutide
WO2026037397A1 (zh) Glp-1类似物的医药用途
HK40094446A (en) Glp-1 dosing regimen
TW202529797A (zh) Glp-1類似物治療代謝疾病的方法及醫藥用途
EP1265629B1 (en) Use of growth hormone in low dose
KR20260022330A (ko) 대사 장애의 치료에 사용하기 위한 glp-1 유사체
TW202532097A (zh) 治療糖尿病及肥胖的方法
HK40083623A (en) Dosing regimen of glp-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260507